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ABSTRACT
Anthrapyridazones, imino analogues of anthraquinone, constitute a family of 
compounds with remarkable anti-cancer activity. To date, over 20 derivatives were 
studied, of which most displayed nanomolar cytotoxicity towards broad spectrum of 
cancer cells, including breast, prostate and leukemic ones. BS-154, the most potent 
derivative, had IC50 values close to 1 nM, however, it was toxic in animal studies. Here, 
we characterize another anthrapyridazone, PDZ-7, which retains high cytotoxicity 
while being well tolerated in mice. PDZ-7 is also active in vivo against anthracycline-
resistant tumor in a mouse xenograft model and induces DNA damage in proliferating 
cells, preferentially targeting cells in S and G2 phases of the cell cycle. Activation of 
Mre11-Rad50-Nbs1 (MRN) complex and phosphorylation of H2AX suggest double-
stranded DNA breaks as a major consequence of PDZ-7 treatment. Consistent with 
this, PDZ-7 treatment blocked DNA synthesis and resulted in cell cycle arrest in late 
S and G2 phases. Analysis of topoisomerase IIα activity and isolation of the stabilized 
covalent topoisomerase IIα - DNA complex in the presence of PDZ-7 suggests that 
this compound is a topoisomerase IIα poison. Moreover, PDZ-7 interfered with actin 
polymerization, thereby implying its action as a dual inhibitor of processes critical for 
dividing cells. Using nuclear magnetic resonance (NMR) spectroscopy we show that 
PDZ-7 interacts with DNA double helix and quadruplex DNA structure. Taken together, 
our results suggest that PDZ-7 is a unique compound targeting actin cytoskeleton 
and DNA.
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INTRODUCTION
Analogues of anthraquinone, including 
anthracyclines (doxorubicin and its derivatives) and 
mitoxantrone, constitute a class of highly active anti-
cancer drugs used broadly in the treatment of wide range 
of malignancies, from leukemias and lymphomas to 
solid tumors [1]. Anthracyclines are frequently assigned, 
along with structurally-unrelated drugs amsacrine and 
etoposide, to a broader class of type II DNA topoisomerase 
inhibitors [2, 3]. In vertebrates, two isoforms of type II 
topoisomerase are present: topoisomerase IIα (Topo 
IIα) and IIβ (Topo IIβ). These enzymes regulate DNA 
structure by creating transient double strand break in one 
DNA helix and passing another helix through the gap, 
before its resealing [3]. Topo IIα is indispensable for 
proliferating cells [4] where it is expressed at high levels. 
Topo IIα is required for DNA replication, condensation of 
mitotic chromosomes and, to lesser extent, transcription 
[5], whereas Topo IIβ is partially redundant and is also 
expressed in non-proliferating cells. Drugs interfering with 
topoisomerase catalytic cycle at the helix resealing step 
(referred to as topoisomerase poisons) lead to formation 
enzyme-associated DNA single- and double-strand breaks 
and are in consequence strongly cytotoxic [2, 3]. DNA 
interacting agents including Top2 inhibitors trigger a 
DNA damage response (DDR), which involves multiple 
proteins acting in sensing and repairing the damage [6]. 
Specifically, DNA lesions activate a network of signaling 
pathways which delay cell cycle progression and activate 
repair mechanisms. Multiple phosphorylation events are 
triggered in the DDR response, many of which are carried 
out by ATM, acting in concert with the Mre11-Rad50-
Nbs1 (MRN) complex [7]. Though some topoisomerase 
II poisons, like etoposide, are extremely specific [8], 
anthraquinone analogues can exert their activity also by 
DNA-crosslinking and alterations in chromatin structure 
[9–11].
Administration of chemotherapy regimens based on 
anthracyclines is limited by accumulative cardiotoxicity 
resulting from reactive oxygen species (ROS) generated 
during iron-dependent redox cycling of the anthraquinone 
moiety [12]. Off-target poisoning of Topo IIβ by the Topo 
IIα inhibitors is thought to be the underlying cause of 
secondary leukemias induced by chemotherapy [13, 14] 
and has been argued to contribute to cardiotoxicity [15]. 
Even with the use of complex liposomal formulations the 
cardiotoxicity remains a major limitation of anthracyclines 
in the clinic [16]. The toxicity of currently used regimens 
could be partially solved by replacing anthracyclines with 
structural analogues selectively targeting Topo IIα and not 
generating ROS [17, 18]. This approach was found to be 
effective in the case of imidazoacridones, a group of type 
II topoisomerase inhibitors [19]. One compound from this 
family, C-1311, entered clinical trials and proved to be 
both well-tolerated in humans and non-cardiotoxic [20].
Anthrapyridazones (2,7-dihydro-3H-dibenzo[de,h]
cinnoline-3,7-diones) constitute a family of imino- 
analogues of anthraquinone with potent activity [21]. 
Symmetric derivatives displayed cytotoxicity in nanomolar 
range and were active towards doxorubicin-resistant 
leukemia cells [21] among others. Asymmetrically 
substituted anthrapyridazones were cytotoxic in low 
nanomolar concentrations against prostate, breast and 
colon cancer cells [22] and retained activity against multi-
drug resistant cells overexpressing ABCB1 and ABCC1 
membrane transporters. Like other anthraquinones, 
anthrapyridazones strongly bind to DNA, but the exact 
mechanism of their pharmacological action is unclear. In 
this report, we describe the molecular mechanism of action 
of compound PDZ-7 (Figure 1A), an anthrapyridazone 
with promising preclinical properties. We compare PDZ-7 
with BS-154, the most potent anthrapyridazone derivative 
characterized to date, in the context of DNA damage 
induction.
RESULTS
PDZ-7 is a potent anticancer compound and an 
inhibitor of DNA topoisomerase IIα
As BS-154 compound had a potent cytotoxic 
activity in preclinical models including cell lines 
derived from various tissues, we tested whether this 
compound exhibits similar anti-cancer activity in vivo. 
When Administered intravenously 3 times once a week 
to BALB/c mice, BS-154 was toxic at doses of 0.75 to 
1 mg/kg (results not shown), suggesting a too narrow 
therapeutic window for a prospective anti-cancer drug 
(MTD<0.75 mg/kg). Conversely, compound PDZ-7 was 
well tolerated by mice at doses up to 50 mg/kg (single 
dose), causing transient decrease in mice body weight at 
the highest dose (Table 1) and no anatomopathological 
abnormalities (not shown). For the preliminary studies 
of in vivo anti-cancer activity LoVo/DX (human colon 
cancer cells with multidrug resistance (MDR) phenotype 
[23]) xenograft mice model was selected. LoVo/DX cells 
were subcutaneously transplanted into Foxn1nu mice and 
measured tumor growth inhibition relative to untreated 
mice over 8 to 24 days. Mice were treated with three 
doses once a week (on days 6, 13, 20) of 15 mg/kg PDZ-7 
or 1 mg/kg doxorubicin. The doses were adjusted for the 
relative toxicity of each drug, with each one amounting to 
ca. 0.3 MTD. Doxorubicin treatment resulted in 15-28% 
tumor growth inhibition, whereas treatment with PDZ-
7 inhibited tumor growth by 36-48% when compared to 
untreated mice (Figure 1B). These results demonstrated 
that PDZ-7 is well tolerated in mice and has anti-cancer 
activity in vivo significantly better than doxorubicin at 
comparable doses in this model. It encouraged us to carry 
out studies to determine its mechanism of action.
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Using publicly available data [22] correlation plots 
between apparent DNA binding constants (Kapp) and 72 
hour cytotoxicity for 23 anthrapyridazone derivatives 
(Figure 1C) were generated. Depending on the cell line 
type, linear determination coefficients (R2) ranged from 
0.59 to 0.71, pointing to DNA as the site of action for 
these drugs. Since our correlation data indicated that 
PDZ-7 can act as a DNA binding agent [22] it was 
tested if PDZ-7 can affect DNA topoisomerases or their 
DNA-complexed forms. Firstly, PDZ-7 was tested in 
a topoisomerase I-mediated pBR322 relaxation assay. 
Addition of PDZ-7 inhibited plasmid relaxation and led 
to a band shift of negatively supercoiled plasmid (Figure 
2A). This result suggested that PDZ-7 could bind DNA. 
We then repeated the electrophoresis in the presence of 
a DNA intercalating agent (chloroquine) in an attempt 
to displace PDZ-7 bound to DNA. Chloroquine causes 
relaxation of negatively supercoiled plasmid and transition 
of relaxed plasmid to supercoiled state, effectively leading 
to reversal of supercoiled and relaxed bands, and allows to 
separate nicked circular DNA from the supercoiled form 
[24]. Under these conditions band migration normalized 
and PDZ-7 was found to completely inhibit Topo I 
at concentrations of 50 and 100 μM (Figure 2B). An 
increased DNA cleavage in the entire concentration range 
of 0.1-100 μM (Figure 2B) was not observed.
Secondly, the experiment with topoisomerase IIα 
(Topo IIα) was conducted and resulted in observation that 
PDZ-7 also inhibits Topo IIα in vitro, fully preventing 
kinetoplast DNA (kDNA) decatenation at concentrations 
of 5 μM or higher (Figure 2C). However, PDZ-7 did not 
induce DNA cleavage as efficiently as etoposide (VP-16), 
a non-intercalative topoisomerase poison [25] (Figure 
2D). A faint band corresponding to linear pBR322 plasmid 
was observed only at 1 μM and not at higher or lower 
concentrations of PDZ-7 (Figure 2D). This suggests that 
in case of PDZ-7 mediated plasmid cleavage the dose-
response follows a bell-shaped curve.
To assure that the result of in vitro topoisomerase 
inhibition is relevant for drug cytotoxic activity, A549 
cells were exposed to equal (10 μM) concentrations 
of PDZ-7, SN-38 and doxorubicin (DOX). High 
concentrations, in comparison to subsequent studies, were 
chosen to compensate low limit of detection of the ICE 
assay. Following one hour treatment, covalent DNA-
protein complexes were isolated by ultracentrifugation 
(Figure 2E). Interestingly, it was evidenced that PDZ-7 
specifically induced protein-DNA complexes only in 
the case of Topo IIα, but not Topo I (Figure 2E). When 
compared with doxorubicin, the amount of Topo IIα-DNA 
complex isolated from cells treated with PDZ-7 was over 2 
times lower (Figure 2F). Thus PDZ-7 is a strong inhibitor 
of topoisomerases I and II in vitro, likely due to its high 
DNA affinity, however this compound induces relatively 
low level of covalent Topo IIα-DNA complexes. Topo IIα 
as a target for PDZ-7 was further confirmed by comparing 
its activity towards cells with altered expression of 
topoisomerase forms. Nalm-6 pre-B leukemia cells with 
heterozygous deletion of Topo IIα (Nalm-6TOP2α+/-) or 
homozygous deletion of Topo IIβ (Nalm-6TOP2β-/-) [17, 
26] were 4.0 times and 1.5-time more resistant to PDZ-
7, respectively (Figure 2G). Altogether these results 
demonstrate that PDZ-7 can cause DNA damage by 
poisoning both type II topoisomerases. However, higher 
Figure 1: PDZ-7 is a DNA binding compound with promising in vivo properties. (A) Chemical structures of anthrapyridazones 
PDZ-7 and BS-154. (B) Tumor growth inhibition by PDZ-7. Athymic Foxn1nu mice were transplanted subcutaneously with doxorubicin-
resistant LoVo/DX colon cancer cells, and xenografts were allowed to grow to 70 mm3. Mice were injected with PDZ-7 (15 mg/kg) or 
doxorubicin (ADR, 1 mg/kg) on days 6, 13 and 20 following tumor transplantation. Mean tumor volumes [mm3] are plotted against days 
after transplantation for control and drug treated mice (10 mice were used for each condition). Both PDZ-7 and doxorubicin were used in 
comparable dose of c.a. 0.3 maximum tolerated dose (MTD). (C) Comparison of DNA affinity of 23 anthrapyridazones, defined as apparent 
DNA binding constant (Kapp, 10
-7 Mol-1) and cytotoxicity in 4 cell models: LNCaP, PC3, DU145 (prostate cancer) and HL-60 (acute myeloid 
leukemia). Linear determination coefficients (R2) calculated for each pair of values are shown in the inset. Two selected compounds, BS-
154 and PDZ-7 are explicitly marked. DNA affinity was measured by ethidium bromide displacement assay and cytotoxicity by manual 
counting after 72-hour exposure to drugs. Original data are disclosed in the granted US Patent [11].
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Table 1: Effect of PDZ-7 administration on BALB/c mice body weight
PDZ-7
Body mass [g], days after injection
1 3 5 8 10
10 mg/kg 21.2 ± 0.3 21.2 ± 0.7 21.2 ± 0.7 21.5 ± 1.0 21.6 ± 0.8
15 mg/kg 21.5 ± 1.0 20.6 ± 1.2 20.6 ± 1.0 20.6 ± 0.9 20.9 ± 1.5
30 mg/kg 20.6 ± 1.6 20.4 ± 1.7 20.2 ± 1.8 20.7 ± 2.0 21.7 ± 1.7
50 mg/kg 20.8 ± 0.6 20.5 ±1.0 18.1 ± 0.9 19.9 ± 1.2 20.5 ± 1.0
BALB/c mice were injected with a single dose of PDZ-7 (10, 15, 30 or 50 mg/kg) in the tail vein and body weight was 
measured every day for a period of 2 weeks. Mean mice weight ± SD for 3 mice is shown for selected time points. 
No statistically relevant changes were noticed.
Figure 2: Anthrapyridazone PDZ-7 is topoisomerase IIα inhibitor. (A) Inhibition of topoisomerase I-mediated pBR322 
relaxation. Reaction was performed either with topoisomerase I alone (+ Topo I), or in the presence of drugs: PDZ-7 (0.1, 0.5, 1, 5, 10, 
50 or 100 μM) and SN-38 (0.1, 1 or 10 μM). Bands corresponding to linear (L), relaxed (R) and negatively supercoiled ((-)Sc) forms of 
pBR322 are marked. (B) Same PDZ-7 samples run in the presence of 40 μg/ml chloroquine, a DNA intercalator which causes inversion of 
R and (-)Sc bands and displaces PDZ-7 from DNA. (C) Inhibition of topoisomerase IIα mediated kDNA decatenation by PDZ-7 (0.1, 0.5, 
1, 5 and 10 μM) in comparison with etoposide (1, 10 and 100 μM). (D) pBR322 cleavage by topoisomerase IIα in the presence of PDZ-7 
(0.1, 1, 10 μM) or etoposide (100 μM). Cleavage product (L, linear DNA) is marked with arrows. (E) Detection of covalent topoisomerase-
DNA complexes (ICE assay) in A549 cells treated for one hour with DMSO (CTR), 10 μM doxorubicin (ADR), SN-38 or PDZ-7. (F) 
Densitometric quantification of data shown in E (mean ± S.D.), calculated from 4 independent experiments. (G) PDZ-7 sensitivity of 
Nalm-6 cells with homozygous deletion of topoisomerase IIβ (TOP2β-/-) or heterozygous deletion of topoisomerase IIα (TOP2α+/-) in 
comparison with wild-type (WT) cells. Data is shown as IC50 calculated from 3 independent experiments. Statistical significance of data 
in F and G was determined with two-tailed Student t-test.
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sensitivity of Nalm-6TOP2α+/- cells in comparison to wild-
type and Nalm-6TOP2β-/- suggests that Topo IIα is a preferred 
target of PDZ-7 in cells.
PDZ-7 and BS-154 are potent inducers of DNA 
damage
Since A549 Non-Small Cell Lung Cancer cell line 
is extensively studied as a model for DNA damaging 
drugs [27–31], it was selected to further elucidate the 
mechanisms of action of the studied compounds. Both 
PDZ-7 and BS-154 displayed potent cytotoxicity towards 
A549 cells, with their respective IC50 values of 6.8 ± 1.5 
nM and 0.14 ± 0.4 nM (Figure 3A). Growth inhibition 
curves were biphasic, with IC50 and IC90 values spread 
far apart (Figure 3A). The latter was approximately 250 
nM for PDZ-7 and 10 nM for BS-154 (Figure 3A). IC90 
concentration of compound PDZ-7 was selected as the 
main reference for further studies on mechanism of action.
It was also investigated whether the differences 
in PDZ-7 and BS-154 activity result from differential 
ability to cause direct or enzyme-mediated DNA strand 
breaks in cells. Using p-Ser139-H2AX (γH2AX) as 
a marker of DNA breaks [32] γH2AX foci through 
immunofluorescence and flow cytometry in cells exposed 
to drugs were detected (Figure 3B-3D). Additionally, a 
uniform level of γH2AX phosphorylation throughout S 
and G2 phases was observed (Figure 3B) and markedly 
lower staining of early G1 cells, independent of the drug 
or concentration used. This finding indicated that DNA 
damage was preferably induced in proliferating cells. 
One hour exposure of A549 cells to PDZ-7 and BS-154 
at concentrations corresponding to their respective IC70 – 
IC90 doses resulted in a concentration-dependent increase 
in histone H2AX phosphorylation and over 3-fold increase 
above the background level, attributed to endogenous 
DNA damage [33] (Figure 3E and 3F). Interestingly, 
γH2AX foci changed in morphology following increasing 
concentrations: at IC70 (25 nM of PDZ-7 and 1 nM of BS-
154) a small and diffused foci were observed and gradually 
coalesced to grainy staining at IC90 concentrations, likely 
resulting from double-strand DNA break (DSB) induction 
(Figure 3C and 3D). The signal intensity of γH2AX 
for PDZ-7 and BS-154 demonstrated a dose-response 
relationship (Figure 3C-3F). BS-154 was stronger in foci 
induction, by over an order of magnitude, yet equitoxic 
concentrations of both drugs induced comparable levels of 
DNA damage, suggesting that their cytotoxicity is a direct 
consequence of DNA breaks. Synchronization of A549 
cells in G1 phase by thymidine block reduced (2-fold) 
PDZ-7 activity consistently with its specificity towards S/
G2 cells (Figure 3G).
To confirm that the grainy γH2AX staining results 
from DSB, activation of Mre11-Rad50-Nbs1 (MRN) DSB 
repair complex [34] in PDZ-7 treated cells was measured. 
After 1-hour exposure to 250 nM PDZ-7 followed by 
post-incubation in drug-free medium an increased 
phosphorylation of Nbs1 at Ser343 that lasted for 24 hours 
was observed (Figure 4A). Elevated phosphorylation 
of Nbs1 points to induction of DSB by PDZ-7 and 
activation of DNA damage response. Then it was further 
tested whether PDZ-7 induces DNA damage other than 
DSB. For this purpose, a panel of hamster cell lines with 
deficient DNA repair pathways was used, including UV- 
hypersensitive mutants deficient in nucleotide-excision 
repair (NER), a DNA repair system responsible for the 
removal of DNA adducts [35]. A sensitivity of cells 
deficient in non-homologous end-joining (NHEJ) and 
homologous recombination (HR) DSB repair pathways 
(Figure 4B) was also compared. Cells deficient in 
endonucleases known to excise damaged DNA fragments, 
XPF and XPG, were more sensitive to PDZ-7 (Figure 4B). 
On the contrary, CSB- and XPD- CHO cells deficient in 
damage recognition and helicase activity, respectively, 
were equally sensitive to PDZ-7 (Figure 4B). A higher 
sensitivity of cells deficient in two pathways of DSB 
repair – xrs6 lacking KU80 (NHEJ pathway) and V-C8 
cells lacking BRCA2 (HR pathway) (Figure 4B) were 
also observed. Hypersensitivity of BRCA2-deficient cells 
to other reports [36, 37] and highlights the role of DSB 
formation in PDZ-7 cytotoxicity.
PDZ-7 induces abnormal perturbations in the 
cell cycle
Continuous treatment with 250 nM PDZ-7 induced 
unusual arrest in G1 and late S phases of the cell cycle 
which lasted for 72 hours (Figure 5A). Concomitantly with 
G1 block, cells that were in early S phase at the time of 
treatment initiation progressed to late S, before arresting. 
This unusual behavior was associated with degradation of 
cyclin B1 and cdc25c and stabilization of both full-length 
and low molecular weight isoforms of cyclin E (Figure 
5C). Brief exposure (1 hour PDZ-7 and post-incubation in 
drug-free medium) induced slow, synchronous progression 
through S phase until arrest in G2, accumulation of cyclins 
A and B1 (Figure 5B). Progression through S phase 
peaked between 6 and 12 hours, before cells finally 
stopped in late G2, as expected from high accumulation of 
cyclin B1 (Figure 5C). In fact, this kind of response during 
treatment is typical for DNA damaging drugs. Moreover, 
PDZ-7 treatment resulted in complete cessation of DNA 
synthesis, revealed by BrdU incorporation after 24 hours 
(Figure 5D) and arrest of mitotic activity, determined by 
MPM-2 staining (Figure 5E).
Interaction of PDZ-7 with the cytoskeleton
The abnormally rounded morphology of A549 cells 
exposed to PDZ-7 for longer periods (>12 hours) was 
observed. It was speculated that PDZ-7 could compromise 
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cytoskeleton functions independently of DNA damage 
response induction. To verify this, the fluorescent co-
staining of F-actin and α-tubulin in cells exposed to PDZ-
7 was performed (Figure 6A and 6B). In cells exposed to 
PDZ-7 for 24 hours an actin aggregation in cortical region 
of the cell and disassembly of actin stress fibers, leading to 
cytokinesis failure and formation of bi-nucleated cells was 
observed (Figure 6A). α-Tubulin cytoskeleton collapsed 
along with actin depolymerization, leading to cell 
rounding. Despite that, polymerized microtubules were 
still present in PDZ 7 treated cells, in stark comparison 
to vinblastine treated cells (Figure 6B, middle and bottom 
panels). PDZ-7 did not cause α-tubulin depolymerization 
in treated cells, in contrast to actin. Moreover these cells 
Figure 3: Anthrapyridazones BS-154 and PDZ-7 induce cytotoxic double stranded DNA breaks. (A) Cytotoxicity of PDZ-
7 and BS-154 towards A549 cells after 120 hours of continuous exposure to each drug, determined by MTT assay. Each point represents 
mean ±S.D. from three independent experiments. (B) Induction of DNA strand breaks after 1 hour of drug treatment with regard to cell 
cycle phase. A549 cells were stained with propidium iodide (DNA content) and anti-γH2AX antibody conjugated to Alexa-594. Percentage 
of cells with high γH2AX level is shown for each scatter plot. (C and D). Dose dependent formation of γH2AX foci after 1 hour of treatment 
with PDZ-7 and BS-154 shown by immunofluorescence. DNA was counterstained with DAPI. Scale bar: 25 μm. (E and F) quantification 
of the median γH2AX fluorescence signal intensity over the nucleus area in. (G) Asynchronously growing or thymidine synchronized A549 
cells were treated with 250 nM PDZ-7 for 1 hour, before anti-γH2AX staining. Quantification of γH2AX was performed as in E and F. Each 
box in panels E-G represents data for 50 nuclei scored and statistical significance was determined using two-tailed Mann-Whitney test.
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were arrested in late S/G2 phases rather than during 
mitosis, as evidenced by (i) lack of staining for MPM-2, 
a mitotic phosphoepitope [38] (Figure 5E), (ii) no spindle 
formation and (iii) no chromatin condensation (Figure 6B). 
It was further supposed that morphology changes resulted 
from actin depolymerization rather than downregulation 
as neither total actin nor α-tubulin was altered in drug-
treated cells (Figure 5C). To confirm that F-actin is a direct 
target for PDZ-7, an in vitro actin polymerization assay 
was performed. PDZ-7 inhibited G-actin polymerization 
and, in contrast to latrunculin A (LanA), it also caused 
depolymerization of residual F-actin present before the 
reaction was initialized (Figure 6C).
DNA binding mode of PDZ-7
High propensity to induce DNA strand break and 
sensitivity of NER-deficient cells to PDZ-7 hinted that 
this compound may interact with DNA in unusual manner 
and perturb its structure, rather than simply inhibit 
topoisomerase IIα. To address this issue, the interaction of 
PDZ-7 with self-complementary double helix oligomers 
d(GCTACG)2 and d(AAGAATTCTT)2 used as models 
for CG- and AT-rich DNA sequences, respectively were 
studied.
1H and 31P NMR titration experiments were 
performed for both oligonucleotides to find possible 
contacts between PDZ-7 and nucleotides. Addition 
of a small amount of PDZ-7 (R, defined as drug to 
oligonucleotide ratio between 0.5 and 0.75), caused 
broadening of the signals of both the exchangeable (12-14 
ppm) and the nonexchangeable protons without relevant 
chemical shift variations (Figure 7A, 7B and 7D). In 
particular, the GC imino protons almost completely 
disappeared in the noise at R= 0.75. 31P NMR was 
further used, which is very sensitive to small changes in 
the geometry of the backbone caused by the interaction 
with the drugs. In our experience, intercalation process is 
associated with a lowfield shift up to 1.0–1.5 ppm because 
of the helix unwinding necessary for accommodation of 
the drug molecule, whereas an electrostatic association 
produces only small and generalized upfield shifts [39–
44]. 31P NMR spectra of d(CGTACG)2, performed at 
R= 0.5 and 1 showed a notable line broadening without 
chemical shift variations (Figure 7C). This spectroscopic 
behavior can exclude an intercalation process and suggests 
a non-specific external interaction of the PDZ-7 with the 
double helix. To better investigate the chemical equilibria 
and to evaluate the relevant species present in solution, a 
DOSY experiment was performed on d(CGTACG)2/PDZ-
7 complex. The diffusion coefficient value (D1) obtained 
is equivalent to a molecular weight of 7.7 kDa, which 
corresponds to one double helix associated with 10 PDZ-
7 molecules or multimeric species in solution. This result 
is consistent with an aggregation process of the PDZ-7, 
likely due to the stacking of the aromatic moiety. The 
significant broadening of all the signals, even for R= 2, did 
not allow to detect NOE contacts between PDZ-7 and both 
oligonucleotides. Therefore, the interaction of PDZ-7 with 
oligonucleotides was not intercalative but rather occurred 
externally between the drug and negatively charged 
backbone of the double helix. Moreover, broadening of 
Figure 4: PDZ-7 induces DNA damage response and is selectively cytotoxic towards DNA repair-deficient cells. (A) 
Induction of DNA-damage response over the course of PDZ-7 treatment. A549 cells were treated with 250 nM PDZ-7 for 1 hour and 
post-incubated in drug-free medium up to 72 hours. Activation of MRN complex was determined by Western Blotting, using antibodies 
towards Nbs1 phosphorylated at Ser343 (p-Nbs1), Mre11 at Ser676 (p-Mre11) and total Rad50. (B) CHO AA8-derived UV sensitive mutants 
with defects in nucleotide excision repair pathway displayed specific sensitivity to PDZ-7. Nuclease-deficient variants UV41 (XPF-) and 
UV135 (XPG-) were 4.0 and 2.2 times more sensitive (IC
50
 value), compared to cells with defects in damage recognition (UV61, CSB-) and 
in helicase activity (UV5, XPD-). Loss of Ku80 protein involved in NHEJ repair in xrs6 cells amounted to 2.2-fold increase in sensitivity 
in comparison to parent CHO-K1 cells. V-C8 cells deficient in DNA damage repair via HR (BRCA2-) had 53-fold lower PDZ 7 IC50 value 
in comparison to parent V79 cells. Statistical significance was determined using two-tailed Student t-test.
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both AT and GC imino protons, which became generalized 
at higher drug to DNA ratios, suggested low specificity of 
the binding.
Furthermore, it was interesting to check if PDZ-7 
can interact more specifically with G-quadruplex DNA 
structures, presumably formed in telomeric and other 
G-rich DNA regions of chromosomes [45]. We used 
d(TTAGGGT)4 as a model of in vitro G-quadruplex-
forming oligonucleotide that does not aggregate and is 
known to form a four stranded G–quadruplex complex 
(parallel strand orientation) [46]. During the titration of 
PDZ-7 in d(TTAGGGT)4 solution the original signals of 
G4-G6 imino experiment exhibited an upfield shifts (Table 
2) broadened at high R values. G4NH changed its shape 
together with the G6 NH imino proton and disappeared 
at low R, but sharpened again for R= 2.0 (Figure 8A). 
The signals of the ligand in the complex (Figure 8B) 
were broad as well, likely due to the movement of the 
PDZ-7 inside the binding site and as a consequence 
of equilibrium between the free and the bound ligand 
Figure 5: PDZ-7 induces unusual perturbations in cell cycle. (A) Continuous exposure to PDZ-7 led to atypical dual G1 / late 
S cell cycle arrest, which persisted up to 72 hours. (B) Short treatment (one hour) and post-incubation in drug-free medium induced 
synchronous progression through S phase and G2 arrest. (C) Expression of cell cycle regulating proteins during prolonged and short 
treatment times was evaluated by Western Blotting. (D) Inhibition of DNA synthesis and S-phase progression by IC90 concentrations of 
PDZ-7 observed independently in two model cell lines: A549 and HL-60 (acute myeloid leukemia). DNA synthesis was determined by 
BrdU incorporation into nascent DNA and detection with anti-BrdU antibodies. BrdU-positive cells are shown for each scatter plot. (E) 
Inhibition of mitotic activity by PDZ-7, determined by staining for mitosis-specific MPM-2 phosphoepitope.
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(Table 3). Again, line broadening and the overlapping 
of aromatic protons of the oligonucleotide with PDZ-7 
aromatic protons made it difficult to observe NOE signals. 
Nonetheless, few NOEs involving the G6 unit (H8 and 
H2’-H2’’) were detected with H2-H3 aromatic protons of 
the PDZ-7 (Figure 8B), together with the broadening and 
upfield shift of G6 NH (-0.5 ppm), suggesting that one 
binding site at the level of G6 is likely to be involved. 
Drug association with G4 did not alter composition of 
G tetrad, as follows from the characteristic inter-strand 
NH-NH interactions (not shown). Interestingly, it was 
observed that the A-tetrad was not conserved, evidenced 
by the lack of the NOEs between G4NH with A3NH2 
and A3H2, which are typical interactions of the A tetrad, 
as well as the NOE of A3H8 with A3H2. Thus it is 
conceivable that a second binding site could be at the 
level of G4 residue even if no NOEs interactions between 
PDZ-7 and G4 were found. Interaction of PDZ-7 at the 
level of G6 tetrad suggests that it can form only a cap-
complex with G-quadruplex.
Figure 6: PDZ-7 causes cytoskeleton destabilization in A549 cells. (A) Changes in phalloidin-stained F-actin cytoskeleton 
morphology and (B) changes in α-tubulin cytoskeleton in A549 cells treated with 250 nM PDZ-7 for 24 hours. 10 μM latrunculin A and 
5 nM vinblastine were used as positive controls for A and B, respectively. Scale bar: 10 μm. (C) Polymerization of rabbit muscle G-actin 
to F-actin in the presence of ATP and DMSO (control) or studied drugs: 100 μM PDZ-7 or 10 μM latrunculin A (LanA). Arrow points to 
polymerization initiation. Note lower initial amount of F-actin in PDZ-7 sample, compared to control.
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DISCUSSION
Preliminary in vivo efficacy studies on PDZ-7 
indicated that this compound has a competitive advantage 
over doxorubicin in low dose treatment of human colon 
cancer xenografts. These optimistic results and future 
potential applications encouraged to study mechanism 
of this phenomenon. To this end, both DNA and actin 
cytoskeleton were identified as two targets for cytotoxic 
anthrapyridazone PDZ-7 in this work. Our mechanistic 
studies were based on previously published data [22], 
which suggested correlation between DNA affinity and 
activity of 23 anthrapyridazones. Interestingly, these two 
parameters have been shown to give poor correlations for 
anthraquinone analogues, including anthracyclines [47], 
and for four-ring heteroaromatic imidazoacridones [48]. 
Similarly to PDZ-7, these above-mentioned compounds 
[49] elicit cytotoxic activity through topoisomerase 
IIα inhibition. During the experiments related to Topo 
I inhibition the unique pattern of DNA migration in the 
presence of PDZ-7 was observed, similar to recently 
reported for isoindoloquinoxinaline derivatives [49]. This 
behavior was proposed to result from non-intercalative 
DNA binding. Structural studies using 1H and 31P NMR 
were conducted and confirmed external binding of PDZ-7 
to the double helix. Our data suggest that nature of Topo 
I and Topo IIα inhibition by PDZ-7 is non-catalytic and 
could result from distortions of DNA structure, which 
prevent complex formation between topoisomerase and 
DNA [50]. Similar effect has been observed for other 
strong DNA-interacting compounds, which attenuate 
topoisomerase reaction cycle through non-catalytic 
mechanisms [50].
Despite low Topo IIα poisoning in cells, PDZ-7 
rapidly induced double stranded DNA breaks as indicated 
by increased phosphorylation of histone H2AX and 
activation of DNA damage response (DDR). Therefore, it 
is conceivable that PDZ-7 induces DNA double-stranded 
Figure 7: PDZ-7 does not bind DNA by intercalation. (A) Imino proton region of d(CGATCG)2 duplex titrated with PDZ-7 from 
R= 0 to 2.0. (B) Aromatic and anomeric proton region of the same spectrum. (C) 31P spectrum of d(CGATCG)2 duplex titrated with PDZ-7. 
(D) Imino proton region of d(AAGAATTCTT)2 duplex titrated with PDZ-7 from R= 0 to 2.0.
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breaks (DSB) through inhibition of strand passage 
reaction and stabilization of topoisomerase cleaved 
complex. However, it may additionally destabilize DNA 
structure or induce other forms of DNA lesions, such as 
single-strand breaks or covalent cross-links. These may 
ultimately convert to DSB [51], or create sensitive sites 
for topoisomerase cleavage [52]. Such interpretation is 
supported by the sensitivity of NER-deficient cells to 
PDZ-7 and DNA binding studies. Our results suggest 
that the endonuclease activity of XPG and XPF [53] is 
important for the removal of PDZ-7 induced DNA lesions, 
while helicase activity of XPD [54] and recognition 
of stalled RNAP by CSB is not [55]. Hypersensitivity 
of BRCA2- cells has been described for other DNA 
damaging compounds, including anthracyclines [35] or 
alkylators ecteinascidin 743 [37], temozolomide [56], 
all of which are clinically used drugs, or experimental 
acronycine derivative S23906-1 [36]. Works of Soares et 
al. [37] and Rocca et al. [36] are of particular relevance 
in this context, as they demonstrate sensitive phenotype 
of BRCA2- cells to DNA damage in comparison to cells 
deficient in other DNA repair proteins. Loss of BRCA2 
protein compromises the repair of double-stranded DNA 
breaks (DSB) via Homologous Recombination (HR), the 
main DSB repair mechanism during S and G2/M phases 
[57]. Without functional HR even low concentration of 
PDZ-7 could be lethal due to accumulation unrepaired 
double strand breaks. Hypersensitivity of BRCA2- cells to 
PDZ-7 provide further evidence that DSB are the direct 
cause of anthrapyridazone cytotoxicity [36, 37].
Both PDZ-7 and BS-154 induced comparable level 
of γH2AX foci at equitoxic concentrations. It is also 
interesting to note that minor exchange of the side chain 
(N-methyl ethylamine in BS-154 to methyl group in PDZ-
7) caused drastic change in anthrapyridazone cytotoxicity 
and tolerance in mice. Histone H2AX was phosphorylated 
at comparable levels from G1/S to G2/M phases of the cell 
cycle, with the only exception for G1 phase cells, which 
Table 2: Chemical shift values of the complex PDZ-7/d(TTAGGGT)4
H2/NH/Me H6/H8 H1’ H2’/H2”
δ Δδb δ Δδ δ Δδ δ Δδ
T1 N.D. N.D. 7.74 +0.15 6.41 +0.22 N.D. N.D.
T2 2.11 -0.06 7.49 +0.01 6.38 -0.05 2.50/2.20 -0.02/-0.03
A3 8.30 +0.05 8.53 -0.13 6.50 +004 3.01/3.01 -0.07/-0.07
G4 11.52 -0.28 7.98 -0.16 6.22 +0.02 2.99/2.69 -0.11/-0.19
G5 11.18 -0.24 7.81 +0.18 6.10 -0.12 2.70/2.75 -0.15/-0.15
G6 10.70 -0.50 7.88 0.00 6.45 +0.01 2.82/2.73 0.00/+0.01
T7 1.80 00.0 7.55 0.00 6.15 -0.11 N.D./2.20 -0.16
Chemical shifts of selected d(TTAGGGT)4 protons were measured in ppm (δ) at 15°C and referenced from external 
standard (2,2-dimethyl-2-silapentane-5-sulfonate). R= 3.0 (PDZ-7/d(TTAGGGT)4), Δδ = δbound - δfree. N.D., not determined.
Figure 8: PDZ-7 binds duplex and quadruplex (G4) DNA. (A) Imino proton region of the 1H NMR titration spectra of duplex 
oligonucleotide d(TTAGGGT)4 with PDZ-7 at 25°C. (B) Proton assignment for PDZ-7 and NOESY spectrum of PDZ-7-d(TTAGGGT)4 
complex at R = 3.S.
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were less susceptible to the PDZ-7 induced DNA damage. 
Similarly, Darzynkiewicz et al. showed that exposure of 
A549 cells to mitoxantrone and etoposide, two Topo IIα 
poisons differing in DNA binding capacities, induced 
DDR throughout the cell cycle [28, 30] and DSB were not 
closely associated with the sites of DNA replication [27].
An interesting finding of our study is that PDZ-
7 acts by more than one mechanism of action and can 
destabilize actin cytoskeleton independently of DNA 
damage. Actin cytoskeleton has long been proposed as 
a target for anti-cancer drugs, due to its implication in 
cancer invasion and metastasis [58]. However, direct 
actin polymerization inhibitors, such as cytochalasins 
or latrunculins are highly toxic [59]. In light of this, it is 
worth noting that PDZ-7 was well tolerated in mice, either 
due to sufficiently low actin depolymerisation activity or 
lower selectivity towards mouse actin. Further studies on 
this issue are required to fully understand this process.
The most effective small-molecule anti-cancer drugs 
elicit their activity on more than one pathway. With this 
regard, anthracyclines have been proposed to have about 
ten distinct modes of action [60, 61]. Recently they have 
been shown to attenuate DDR through displacement of 
histones (including H2AX) from damaged chromatin 
[11] and to interact with DNA G-quadruplexes [62]. 
On the other hand, cytoskeleton-destabilizing drugs 
inhibit trafficking of repair proteins, apart from their 
antimitotic activity [63]. Therefore it is often challenging 
to determine, which modes of action are truly important 
for the anticancer activity [60].
Therefore, here, we suggest that the inhibition of 
DNA synthesis and mitotic activity by PDZ-7 is, alike with 
anthracyclines, merely a consequence of DNA damage. In 
A549 cells, exposure time played decisive role with regard 
to dominant mechanism: at short exposure times PDZ-7 
behaved as a typical DNA damaging agent, activating 
rapid DNA damage response and cell cycle arrest in G2 
phase, supported by the observed pattern of growth arrest. 
However, longer exposures led to actin disassembly 
blocking cell cycle in G1 phase and in late S or tetraploid 
(bi-nucleate) G1. Additionally, we show that unusual cell 
cycle perturbation by PDZ-7 is associated with differential 
expression of cyclins A, B and E. Thus, it is predicted that 
in the in vivo setting, where drug concentration spikes, 
followed by rapid clearance from plasma, DNA damaging 
effect of PDZ-7 will be the most dominant.
Owing to its high activity and relatively low animal 
toxicity, PDZ-7 or related anthrapyridazones emerge as 
potential anticancer agents and encourage their further pre-
clinical development. The exact nature of PDZ-7-induced 
DNA lesions is not fully understood and therefore requires 
further investigation. In particular, it is interesting to check 
whether PDZ-7 can induce DNA damage by interacting 
with enzymes other than DNA topoisomerases and if actin 




Anthrapyridazones PDZ-7 and BS-154 were 
synthesized by Dr Malgorzata Wysocka (BLIRT S.A., 
Gdansk), as described [22]. Doxorubicin, etoposide, 
latrunculin A and SN-38 were purchased from Sigma-
Aldrich (Poznan, Poland). All drugs were dissolved in 
DMSO to concentrations of 2 or 10 mM and stored at 
-20°C.
In vivo experiments
In vivo toxicity studies were performed on 8-10 
week old female BALB/c mice and in vivo therapeutic 
efficacy studies in athymic Foxn1nu mice. Mice were 
Table 3: Chemical shift values of PDZ-7 free and in the complex with d(TTAGGGT)4
PDZ-7 Free Bound Δδ
H-6 7.70 7.60 -0.10
H-5 6.89 6.69 -0.20
H-4 8.08 7.78 -0.30
H-1 7.72 7.25 -0.47
H-2 7.69 7.25 -0.44
H-3 7.69 7.25 -0.44
CH2N
+ 4.40/4.78 N.D. N.D.
CH2N 3.50/3.00 N.D. N.D.
CH3 2.90/2.99 2.60 -0.30/-0.39
Refer to Table 3. N.D., not determined.
Oncotarget105149www.impactjournals.com/oncotarget
held in specific pathogen-free conditions and granted free 
access to food and water. To determine MTD, PDZ-7 was 
dissolved in 0.9% NaCl and single dose (10, 15, 30 or 
50 mg of drug per kg body weight, 0.01 ml per 1 g body 
weight) was injected into BALB/c mouse tail vein (3 mice 
per dose). Body weight of mice was monitored every day 
for two weeks, after which time mice were sacrificed and 
subjected to anatomopathological analysis. In the initial in 
vivo efficacy study aimed to determine anticancer activity, 
10 × 106 LoVo/DX cells were subcutaneously transplanted 
into Foxn1nu mice (10 mice per condition). Tumors were 
allowed to grow to 70 mm3, after which mice were treated 
with three doses once a week (days 6, 13, 20) of 15 mg 
PDZ-7 (ca. 0.3 MTD; cumulative dose of 45 mg/kg) or 1 
mg doxorubicin (ca. 0.3 MTD; cumulative dose of 3 mg/
kg) per kg body weight. Tumor volume was determined 
every 3 days and mice were anesthetized with isoflurane 
and euthanized 24 days after xenotransplantation. All in 
vivo studies were performed according to Interdisciplinary 
Principles and Guidelines for the Use of Animals in 
Research, Marketing and Education issued by the New 
York Academy of Sciences’ Ad Hoc Committee on Animal 
Research and were approved by the First Local Committee 
for Experiments with the Use of Laboratory Animals, 
Wroclaw, Poland.
Cell lines
A549 and HL-60 cells were from ATCC. Nalm-
6 topoisomerase knock-out cells, originally obtained by 
Noritaka Adachi (Yokohama City University, Japan), 
were kindly provided by Caroline Austin and Ian Cowell 
(Newcastle University, UK). CHO-AA8, CHO-K1 
and V79 cells, along with their DNA repair deficient 
variants, were provided by Malgorzata Zdzienicka 
(Leiden University, Netherlands). A549, HL-60, Nalm-6 
and derived cells were cultured in RPMI-1640 medium 
(Corning 15-040-CV); CHO-K1, CHO-AA8 and all 
derived cells were cultured in F-10 Ham medium (Corning 
10-070-CV). Media were supplemented with 10% FBS 
(Sigma–Aldrich F7524) and antibiotics: penicillin (60 
μg/ml) and streptomycin (42.4 μg/ml). LoVo/DX cells 
were cultured in 1:1 (v/v) mixture of RPMI-1640 and 
Opti-MEM (both IIET, Wroclaw, Poland) supplemented 
with 5% FBS (F7524), 2 mM L-glutamine (G8540), 
1mM sodium puryvate (P4562) (all Sigma-Aldrich, 
Poznan, Poland), 0.1 μg/ml doxorubicin (Medac GmbH, 
F130421A) and antibiotics: penicillin (60 μg/ml) and 
streptomycin (100 μg/ml). All cells were maintained at 
37°C in humidified atmosphere of 5% CO2 and 95% air 
and routinely screened for Mycoplasma contamination.
Actin polymerization assay
Experiment was carried out with Actin 
polymerization kit (Cytoskeleton #BK003) according to 
manufacturer’s instructions. Briefly, 0.4 mg/ml pyrene-
labelled rabbit muscle G-actin was suspended at in 0.2 mM 
CaCl2, 5 mM Tris-HCl, pH 8.0, allowed to depolymerize 
(1 hour, 4°C) and cleared by centrifugation (16,100 x g, 
30 minutes, 4°C). Tested compounds diluted in DMSO 
(final concentration 1%) were added to G-actin solution 
and baseline fluorescence was determined (20 minutes, 
RT). Polymerization was initiated by the addition of 50 
mM KCl, 2 mM MgCl2, 5 mM guanidine carbonate, 1 mM 
ATP, 10 mM Tris-HCl, pH 7.5 (final concentrations) and 
allowed to proceed for 1 hour. Data was gathered using 
Tecan Infinite M1000PRO in kinetic mode. Fluorescence 
was read using excitation wavelength set to 350 ± 20 nm 
and emission wavelength to 410 ± 10 nm every 30 seconds 
from the moment of compound addition until the signal 
reached plateau.
Topoisomerase inhibition assays
Reaction mixture contained 50 ng pBR322 plasmid 
DNA (Thermo Scientific #SD0041), 40 mM Tris-HCl (pH 
7.5), 120 mM KCl, 10 mM MgCl2, 1.1 mM EDTA, 10 mM 
β-mercaptoethanol, 100 μg/ml BSA and drug diluted in 
DMSO (final concentration 5%) was prepared and reaction 
was initiated by the addition of 5 μl (total reaction volume 
10 μl) human recombinant Topo1 diluted in reaction buffer 
and allowed to proceed for 30 minutes at 37°C. Reactions 
were terminated by the addition of 5-times concentrated 
loading buffer (0.1% SDS, 5% sucrose, 2.5 mM EDTA 
0.05% bromophenol blue in ddH2O, final concentrations). 
Samples were resolved in 1% agarose gel in TBE for 12 h 
at constant voltage of 1 V/cm and current not exceeding 20 
mA. Gel was stained with ethidium bromide, destained in 
TBE and photographed under UV illumination.
For Topo IIα (Topogen TG2013), reaction mixture 
contained 200 ng kDNA, 50 mM Tris-HCl (pH 7.5), 150 
mM NaCl, 10 mM MgCl2, 5 mM ATP, 0.5 mM DTT, 30 
μg/ml BSA and reactions were terminated by the addition 
of 1% sarkosyl, 5% glycerol 0.05% bromophenol blue 
in ddH2O, final concentrations. Cleavage was performed 
with 200 ng pBR322 in same buffer and the reactions were 
stopped by addition of 0.3 mg/ml proteinase K in 0.35% 
SDS, 15 mM EDTA and topoisomerase digestion (90 
minutes, 50°C), before adding loading buffer.
Topoisomerase inhibition in cells was determined 
using ICE assay as described [64]. In brief, cells were 
lysed in 1% sarkosyl in TE, DNA was sheared with 
26G needle, separated on 1.5 g/ml CsCl2 cushion using 
SW55Ti rotor (Beckmann), (121,000 × g, 20 hours, 
4°C) and spot-blotted on nitrocellulose membrane. 
Topoisomerases were detected with mouse anti-
Topoisomerase I IgM (1:100, BD Biosciences 556597) 
and rat anti-IgM IgG2a, κ (1:200, BD Biosciences 553435) 
or anti-Topoisomerase IIα IgG1 (1:100, BD Biosciences 




A549, CHO-AA8, CHO-K1, V-79 and derived cell 
lines we seeded in 24-well plates at 4,000 cells/per well 
and allowed to attach overnight. Subsequently, drugs 
diluted in culture medium (final DMSO concentration 
0.5%) were added and cells were incubated for 120 hours 
in the presence of drug. Nalm-6 cells were seeded at 
50,000 cells/ml and drugs were added immediately. Cell 
survival was determined with MTT assay. Briefly, MTT 
diluted in PBS was added to a final concentration of 0.4 
mg/ml and after 4 hours (37°C) medium was aspirated. 
Precipitated and dried formazan crystals were dissolved 
in DMSO and absorbance was read using 540 nm 
measurement filter and 650 nm reference.
Flow cytometry
A549 cells were seeded in Petri dishes, allowed to 
attach overnight and treated as indicated. Drug-treated 
cells were harvested, fixed with 70% ethanol (overnight 
or longer, -20°C), rehydrated in PBS, stained with 20 μg/
ml propidium iodide and 100 μg/ml RNase A in PBS (1 
hour, RT) and analysed directly. To detect DNA synthesis, 
cells were labelled with 20 μM 5-bromo-2'-deoxyuridine 
(BrdU) for 1 hour before treatment end and fixed in 70% 
ethanol (overnight or longer, -20°C). Following brief 
rehydration with PBS (10 minutes on ice), DNA was 
denatured with 2 M HCl (30 minutes, RT) and suspension 
was neutralized with 0.1 M sodium tetraborate, pH 8.5 
(10 minutes, RT). Cells were blocked with 1% BSA in 
PBS (15 minutes, RT), incubated with mouse anti-BrdU 
antibody (1:100, CalBioChem #NA61, 1 hour, 37°C), 
and incubated with anti-mouse FITC-conjugated donkey 
antibody (1:200, Jackson 715-095-151, 30 minutes, 
37°C). To detect mitotic cells, ethanol-fixed cells were 
rehydrated with PBS (10 minutes on ice), blocked with 
1% BSA in PBS and incubated with mouse anti-MPM2 
antibody (1:100, DAKO M3514, 1 hour, 37°C), and anti-
mouse FITC-conjugated donkey antibody (1:100, Jackson 
715-095-151, 45 minutes, 37°C). To detect DNA damage, 
ethanol-fixed cells were rehydrated with PBS (10 minutes 
on ice), washed three times with 1% BSA in PBS and 
incubated with Alexa488-conjugated mouse anti-γH2AX 
antibody (1:40, BioLegend #613406, 1 hour, 37°C). For 
BrdU, MPM-2 and γH2AX, DNA was counterstained 
with 5 μg/μl propidium iodide and 100 μg/μl RNaseA in 
PBS (30 minutes, RT) and cells were processed by flow 
cytometry. 10,000 cells were scored for each assay.
Immunofluorescence
A549 cells were seeded on coverslips, allowed to 
attach overnight and treated as indicated. Drug-treated 
cells were fixed and permeabilized in a single step with 
50% acetone/methanol (2 minutes, RT), blocked with 
0.5% BSA, 0.2% cold-water fish skin gelatin in PBS 
(30 minutes, RT), incubated with mouse anti-γH2AX 
antibody (1:200, Millipore 05-636, 60 minutes, 37°C), 
and anti-mouse Alexa-594 conjugated donkey antibody 
(1:100, Jackson Immuno Research 715-585-150, 30 
minutes, 37°C). DNA was counterstained with 0.1 μg/ml 
DAPI (10 minutes, RT), coverslips were mounted in 25 
mg/ml 1,4-diazabicyclo [2, 2, 2]octane (DABCO) in 50% 
glycerol in PBS and sealed with nail polish. Images were 
acquired under fluorescence microscope using identical 
settings for every sample. Fluorescence intensity of 
γH2AX was quantified as Median Fluorescence Intensity 
(MFI) over the nuclear area of each cell. Nuclear area was 
determined by applying automatic thresholding procedure 
on the images of DAPI-stained cells and γH2AX MFI was 
calculated inside the selected area. All operations were 
performed on greyscale 16-bit tiff images.
For α-tubulin, cells were fixed and permeabilized 
with methanol (20 minutes. -20°C), blocked with 1% BSA 
in PBS and incubated with mouse anti-α-tubulin antibody 
(1:300, Amersham N365, 60 minutes, 37°C) and anti-
mouse DyLight-488 conjugated donkey antibody (1:100, 
Pierce SA5-10166, 60 minutes, 37°C). F-actin was stained 
with 0.5 μg/ml TRITC conjugated phalloidin (Sigma-
Aldrich P1951, 20 minutes, RT) in PBS in cells fixed with 
4% formaldehyde (10 minutes, 4°C) and permeabilized 
with 0.5% Triton X-100 (10 minutes, RT). DNA was 
stained as described above.
Western blotting
Cells were lysed in RIPA buffer (5 mM EDTA, 
0,1% (w/v) SDS, 1% (v/v) NP-40, 0,5% (w/v) sodium 
deoxycholate, 150 mM NaCl, 50 mM Tris pH 7.4) with an 
addition of the commercially available protease inhibitor 
cocktail (Roche) and phosphatase inhibitors: 50 mM 
NaF, 50 mM β-glycerophosphate and 1 mM Na3VO4 (30 
minutes on ice). Lysates were cleared at 16,100 x g (4°C, 
10 minutes) and protein concentration was measured with 
BCA assay (Thermo Scientific 23227). Equal amounts 
of protein were prepared in Laemmli Buffer and loaded 
on polyacrylamide (7.5, 10 or 12%) gels. SDS PAGE 
gels were resolved in Running Buffer (15 minutes at 
constant 100 V and 50 minutes at 200 V). Proteins were 
transferred on the pre-wet polyvinylidene fluoride (PVDF) 
membranes in Transfer Buffer (3 hours at constant current 
of 250 mA, 4°C). PVDF membranes were blocked in 
5% BSA in TBST, and incubated (overnight, 4°C) with 
appropriate primary antibodies: anti-Cyclin A (1:200, 
Santa Cruz sc-596), anti-Cyclin B1 (1:100, Santa Cruz 
sc-245), anti-Cyclin D1 (1:1,000, Cell Signaling #2926), 
anti-Cyclin E (1:200, Santa Cruz sc-247), anti-cdc25c 
(1:200, Santa Cruz sc-327), anti-cdk (1:200, Santa Cruz 
sc-163), anti-Actin (1:600, Santa Cruz sc-1616), anti-α-
tubulin (1:5,000, Amersham N356), anti-p-Nbs1 (1:250, 
Cell Signaling #3001), anti-Nbs1 (1:500, Cell Signaling 
#14956), anti-p-Mre11 (1:250, Cell Signaling #4859), 
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anti-Mre11 (1:1,000, Cell Signaling #4847), anti-Rad50 
(1:1,000, Cell Signaling #3427). Next, membranes 
were incubated with secondary anti-mouse, anti-rabbit 
and anti-goat antibodies (All at 1:10,000, Jackson 
ImmunoResearch 715-035-150, 711-035-152, 705-
036-147) and X-ray films (Agfa) were developed using 
enhanced chemiluminescence (SuperWest Pico, Thermo 
Scientific).
NMR
Oligonucleotides samples were prepared at a 
0.25-0.40 mM concentration range, in H2O/D2O (9:1) 
containing 10 mM NaH2PO4/Na2HPO4 and 100 mM NaCl, 
pH 6.8 for the d(CGTACG)2 and d(AAGAATTCTT)2 
oligonucleotides (Eurofins Genomics Italy, Milan). For the 
G-quadruplex d(TTAGGGT)4 studies buffer containing 25 
mM KH2PO4, 150 mM KCl and 1 mM EDTA, pH 6.7 was 
used. The oligonucleotide samples were heated to 85°C for 
1 minute and then cooled at room temperature overnight. 
Stock solutions of PDZ-7 were prepared in DMSO-d6.
The 1H spectra were acquired at variable temperature 
of 15°C and 25°C and were referenced to external DSS 
(2,2-dimethyl-2-silapentane-5-sulfonate sodium salt) set at 
0.00 ppm. Chemical shifts (δ) were measured in ppm. 31P 
NMR spectra was recorded at 242.94 MHz and referenced 
at 1% H3PO4 (external reference). 
1H NMR titrations were 
performed by adding increasing amounts of the drug to the 
oligonucleotide solution until R= [drug]/[oligonucleotide] 
= 2.0 or 4.0 was reached. Phase sensitive NOESY spectra 
were acquired in TPPI mode, with 2048 x 1024 complex 
FIDs and mixing times ranging from 200 ms to 400 ms. All 
spectra were transformed and weighted with a 90° shifted 
sine-bell squared function to 4K x 4K real data points. 
Pseudo two-dimensional DOSY [65] experiments were 
acquired using the pulse-program “stebpgp1s” and raw 
data were processed using the standard DOSY software 
present in the Bruker library (TOPSPIN v. 1.3). All NMR 
spectra were recorded on a Bruker AV600 spectrometer 
operating at a frequency of 600.10 MHz.
Software and equipment
Microscopy images were captured with Olympus 
BX60 epifluorescent microscope coupled to XC50 CCD 
camera and analysed in Fiji [66]. Flow cytometry was 
performed using Guava EasyCyte 8HT (Merck) and 
analysed with Guava Soft 2.7 InCyte (Merck) or Flowing 
Software 2.5.1. Statistical analysis was performed with 
GraphPad Prism 5 and uniform significance levels were 
used through the entire manuscript: * p<0.05; ** p<0.01; 
*** p<0.001.
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